AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG
Contact:
Dr. Christoph Klade
Phone:
E-Mail: christoph.klade@aoporphan.com
KEYWORDS:
  • European Union
  • Polycythemia Vera (PV)
  • progress
  • Ropeginterferon alfa-2b
  • European Marketing Authorization Procedure
  • AOP Orphan
Download Photos
AOP Orphan Pharmaceuticals AG (8 releases)

* AOP Orphan's submission for marketing authorization of Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) in the European Union (EU) has resumed after clock-stop. The conclusion of this centralized procedure is expected for Q4/2018. [more]

AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
2018-03-22, pts20180322023 Products/Innovations, Science/Technology
AOP Orphan announces two-year results on Ropeginterferon alfa-2bin PV
2017-12-10, pts20171210001 Health/Medicine, Science/Technology
AOP Orphan Pharmaceuticals AG to acquire Selisistat
2017-10-02, pts20171002022 Products/Innovations, Health/Medicine
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations